Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 224

1.

Dysfunction of Poly (ADP-Ribose) Glycohydrolase Induces a Synthetic Lethal Effect in Dual Specificity Phosphatase 22-Deficient Lung Cancer Cells.

Sasaki Y, Fujimori H, Hozumi M, Onodera T, Nozaki T, Murakami Y, Ashizawa K, Inoue K, Koizumi F, Masutani M.

Cancer Res. 2019 Aug 1;79(15):3851-3861. doi: 10.1158/0008-5472.CAN-18-1037. Epub 2019 May 29.

PMID:
31142510
2.

Inactive immune pathways in triple negative breast cancers that showed resistance to neoadjuvant chemotherapy as inferred from kinase activity profiles.

Sawada T, Hilhorst R, Rangarajan S, Yoshida M, Tanabe Y, Tamura K, Kinoshita T, Shimoyama T, van Beuningen R, Ruijtenbeek R, Tsuda H, Koizumi F.

Oncotarget. 2018 Sep 28;9(76):34229-34239. doi: 10.18632/oncotarget.26026. eCollection 2018 Sep 28.

3.

Preclinical and phase I clinical studies of KW-2450, a dual IGF-1R/IR tyrosine kinase inhibitor, in combination with lapatinib and letrozole.

Umehara H, Maekawa Y, Koizumi F, Shimizu M, Ota T, Fouad TM, Willey J, Kaito H, Shiraishi N, Nakashima D, Akinaga S, Ueno NT.

Ther Adv Med Oncol. 2018 Jul 30;10:1758835918786858. doi: 10.1177/1758835918786858. eCollection 2018.

4.

Correction: Radiotherapy increases plasma levels of tumoral cell-free DNA in non-small cell lung cancer patients.

Kageyama SI, Nihei K, Karasawa K, Sawada T, Koizumi F, Yamaguchi S, Kato S, Hojo H, Motegi A, Tsuchihara K, Akimoto T.

Oncotarget. 2018 May 4;9(34):23844. doi: 10.18632/oncotarget.25378. eCollection 2018 May 4.

5.

Radiotherapy increases plasma levels of tumoral cell-free DNA in non-small cell lung cancer patients.

Kageyama SI, Nihei K, Karasawa K, Sawada T, Koizumi F, Yamaguchi S, Kato S, Hojo H, Motegi A, Tsuchihara K, Akimoto T.

Oncotarget. 2018 Apr 10;9(27):19368-19378. doi: 10.18632/oncotarget.25053. eCollection 2018 Apr 10. Erratum in: Oncotarget. 2018 May 4;9(34):23844.

6.

PARG Inhibitors and Functional PARG Inhibition Models.

Sasaki Y, Hozumi M, Fujimori H, Murakami Y, Koizumi F, Inoue K, Masutani M.

Curr Protein Pept Sci. 2016;17(7):641-653.

PMID:
27817742
7.

Prognostic Impact of Circulating Tumor Cell Detected Using a Novel Fluidic Cell Microarray Chip System in Patients with Breast Cancer.

Sawada T, Araki J, Yamashita T, Masubuchi M, Chiyoda T, Yunokawa M, Hoshi K, Tao S, Yamamura S, Yatsushiro S, Abe K, Kataoka M, Shimoyama T, Maeda Y, Kuroi K, Tamura K, Sawazumi T, Minami H, Suda Y, Koizumi F.

EBioMedicine. 2016 Sep;11:173-182. doi: 10.1016/j.ebiom.2016.07.027. Epub 2016 Jul 27.

8.

Clinical and microarray analysis of breast cancers of all subtypes from two prospective preoperative chemotherapy studies.

Okuma HS, Koizumi F, Hirakawa A, Nakatochi M, Komori O, Hashimoto J, Kodaira M, Yunokawa M, Yamamoto H, Yonemori K, Shimizu C, Fujiwara Y, Tamura K.

Br J Cancer. 2016 Aug 9;115(4):411-9. doi: 10.1038/bjc.2016.184. Epub 2016 Jul 14.

9.

Sensitive cytometry based system for enumeration, capture and analysis of gene mutations of circulating tumor cells.

Sawada T, Watanabe M, Fujimura Y, Yagishita S, Shimoyama T, Maeda Y, Kanda S, Yunokawa M, Tamura K, Tamura T, Minami H, Koh Y, Koizumi F.

Cancer Sci. 2016 Mar;107(3):307-14. doi: 10.1111/cas.12868. Epub 2016 Feb 23.

10.

High-Density Dielectrophoretic Microwell Array for Detection, Capture, and Single-Cell Analysis of Rare Tumor Cells in Peripheral Blood.

Morimoto A, Mogami T, Watanabe M, Iijima K, Akiyama Y, Katayama K, Futami T, Yamamoto N, Sawada T, Koizumi F, Koh Y.

PLoS One. 2015 Jun 24;10(6):e0130418. doi: 10.1371/journal.pone.0130418. eCollection 2015.

11.

Back with a vengeance: microvascular tumor embolism.

Yunokawa M, Tsuta K, Tanaka T, Nara E, Koizumi F, Ito J, Sekine S, Fujiwara Y, Tamura K.

Am J Med. 2015 Aug;128(8):834-6. doi: 10.1016/j.amjmed.2015.04.004. Epub 2015 Apr 23. No abstract available.

PMID:
25912204
12.

Chemotherapy-Regulated microRNA-125-HER2 Pathway as a Novel Therapeutic Target for Trastuzumab-Mediated Cellular Cytotoxicity in Small Cell Lung Cancer.

Yagishita S, Fujita Y, Kitazono S, Ko R, Nakadate Y, Sawada T, Kitamura Y, Shimoyama T, Maeda Y, Takahashi F, Takahashi K, Tamura T, Koizumi F.

Mol Cancer Ther. 2015 Jun;14(6):1414-23. doi: 10.1158/1535-7163.MCT-14-0625. Epub 2015 Apr 1.

13.

Long-term complete remission in a patient with intravascular large B-cell lymphoma with central nervous system involvement.

Sawada T, Omuro Y, Kobayashi T, Hishima T, Koizumi F, Kanemasa Y, Shimoyama T, Sasaki E, Maeda Y.

Onco Targets Ther. 2014 Nov 18;7:2133-6. doi: 10.2147/OTT.S72596. eCollection 2014.

14.

Enhanced anti-tumor effect of zoledronic acid combined with temozolomide against human malignant glioma cell expressing O6-methylguanine DNA methyltransferase.

Fukai J, Koizumi F, Nakao N.

PLoS One. 2014 Aug 11;9(8):e104538. doi: 10.1371/journal.pone.0104538. eCollection 2014.

15.

Pharmacodynamic change in plasma angiogenic proteins: a dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib.

Koyama N, Saito K, Nishioka Y, Yusa W, Yamamoto N, Yamada Y, Nokihara H, Koizumi F, Nishio K, Tamura T.

BMC Cancer. 2014 Jul 21;14:530. doi: 10.1186/1471-2407-14-530.

16.

Design and synthesis of phenolic hydrazide hydrazones as potent poly(ADP-ribose) glycohydrolase (PARG) inhibitors.

Islam R, Koizumi F, Kodera Y, Inoue K, Okawara T, Masutani M.

Bioorg Med Chem Lett. 2014 Aug 15;24(16):3802-6. doi: 10.1016/j.bmcl.2014.06.065. Epub 2014 Jun 27.

PMID:
25042255
17.

Tocilizumab, a proposed therapy for the cachexia of Interleukin6-expressing lung cancer.

Ando K, Takahashi F, Kato M, Kaneko N, Doi T, Ohe Y, Koizumi F, Nishio K, Takahashi K.

PLoS One. 2014 Jul 10;9(7):e102436. doi: 10.1371/journal.pone.0102436. eCollection 2014.

18.

Activated PI3K/AKT and MAPK pathways are potential good prognostic markers in node-positive, triple-negative breast cancer.

Hashimoto K, Tsuda H, Koizumi F, Shimizu C, Yonemori K, Ando M, Kodaira M, Yunokawa M, Fujiwara Y, Tamura K.

Ann Oncol. 2014 Oct;25(10):1973-9. doi: 10.1093/annonc/mdu247. Epub 2014 Jul 9.

PMID:
25009009
19.

A novel flow cytometry-based cell capture platform for the detection, capture and molecular characterization of rare tumor cells in blood.

Watanabe M, Serizawa M, Sawada T, Takeda K, Takahashi T, Yamamoto N, Koizumi F, Koh Y.

J Transl Med. 2014 May 23;12:143. doi: 10.1186/1479-5876-12-143.

20.

Synergistic anti-tumor effects of a novel phosphatidyl inositol-3 kinase/mammalian target of rapamycin dual inhibitor BGT226 and gefitinib in non-small cell lung cancer cell lines.

Katanasaka Y, Kodera Y, Yunokawa M, Kitamura Y, Tamura T, Koizumi F.

Cancer Lett. 2014 Jun 1;347(2):196-203. doi: 10.1016/j.canlet.2014.02.025. Epub 2014 Mar 7.

PMID:
24614285
21.

Hypoxia increases gefitinib-resistant lung cancer stem cells through the activation of insulin-like growth factor 1 receptor.

Murakami A, Takahashi F, Nurwidya F, Kobayashi I, Minakata K, Hashimoto M, Nara T, Kato M, Tajima K, Shimada N, Iwakami S, Moriyama M, Moriyama H, Koizumi F, Takahashi K.

PLoS One. 2014 Jan 28;9(1):e86459. doi: 10.1371/journal.pone.0086459. eCollection 2014.

22.

Predictors for delayed encephalopathy following acute carbon monoxide poisoning.

Kudo K, Otsuka K, Yagi J, Sanjo K, Koizumi N, Koeda A, Umetsu MY, Yoshioka Y, Mizugai A, Mita T, Shiga Y, Koizumi F, Nakamura H, Sakai A.

BMC Emerg Med. 2014 Jan 31;14:3. doi: 10.1186/1471-227X-14-3.

23.

Clinicopathological features in young patients treated for small-cell lung cancer: significance of immunohistological and molecular analyses.

Taniyama TK, Nokihara H, Tsuta K, Horinouchi H, Kanda S, Fujiwara Y, Yamamoto N, Koizumi F, Yunokawa M, Tamura T.

Clin Lung Cancer. 2014 May;15(3):244-7. doi: 10.1016/j.cllc.2013.06.012. Epub 2013 Dec 14.

PMID:
24456892
24.

Multicolor detection of rare tumor cells in blood using a novel flow cytometry-based system.

Watanabe M, Uehara Y, Yamashita N, Fujimura Y, Nishio K, Sawada T, Takeda K, Koizumi F, Koh Y.

Cytometry A. 2014 Mar;85(3):206-13. doi: 10.1002/cyto.a.22422. Epub 2013 Dec 10.

25.

Silencing of poly(ADP-ribose) glycohydrolase sensitizes lung cancer cells to radiation through the abrogation of DNA damage checkpoint.

Nakadate Y, Kodera Y, Kitamura Y, Tachibana T, Tamura T, Koizumi F.

Biochem Biophys Res Commun. 2013 Nov 29;441(4):793-8. doi: 10.1016/j.bbrc.2013.10.134. Epub 2013 Nov 6.

PMID:
24211580
26.

KRAS mutation confers resistance to antibody-dependent cellular cytotoxicity of cetuximab against human colorectal cancer cells.

Nakadate Y, Kodera Y, Kitamura Y, Shirasawa S, Tachibana T, Tamura T, Koizumi F.

Int J Cancer. 2014 May 1;134(9):2146-55.

27.

Phase 1 study of lenvatinib combined with carboplatin and paclitaxel in patients with non-small-cell lung cancer.

Nishio M, Horai T, Horiike A, Nokihara H, Yamamoto N, Takahashi T, Murakami H, Yamamoto N, Koizumi F, Nishio K, Yusa W, Koyama N, Tamura T.

Br J Cancer. 2013 Aug 6;109(3):538-44. doi: 10.1038/bjc.2013.374. Epub 2013 Jul 16.

28.

Clinical impact of pentraxin family expression on prognosis of pancreatic carcinoma.

Kondo S, Ueno H, Hosoi H, Hashimoto J, Morizane C, Koizumi F, Tamura K, Okusaka T.

Br J Cancer. 2013 Aug 6;109(3):739-46. doi: 10.1038/bjc.2013.348. Epub 2013 Jul 4.

29.

Epidermal growth factor receptor variant type III markedly accelerates angiogenesis and tumor growth via inducing c-myc mediated angiopoietin-like 4 expression in malignant glioma.

Katanasaka Y, Kodera Y, Kitamura Y, Morimoto T, Tamura T, Koizumi F.

Mol Cancer. 2013 Apr 25;12:31. doi: 10.1186/1476-4598-12-31.

30.

Hypoxia induces gefitinib resistance in non-small-cell lung cancer with both mutant and wild-type epidermal growth factor receptors.

Minakata K, Takahashi F, Nara T, Hashimoto M, Tajima K, Murakami A, Nurwidya F, Yae S, Koizumi F, Moriyama H, Seyama K, Nishio K, Takahashi K.

Cancer Sci. 2012 Nov;103(11):1946-54. doi: 10.1111/j.1349-7006.2012.02408.x. Epub 2012 Sep 14.

31.

Circulating endothelial cells and other angiogenesis factors in pancreatic carcinoma patients receiving gemcitabine chemotherapy.

Kondo S, Ueno H, Hashimoto J, Morizane C, Koizumi F, Okusaka T, Tamura K.

BMC Cancer. 2012 Jun 25;12:268. doi: 10.1186/1471-2407-12-268.

32.

Efficacy of everolimus, a novel mTOR inhibitor, against basal-like triple-negative breast cancer cells.

Yunokawa M, Koizumi F, Kitamura Y, Katanasaka Y, Okamoto N, Kodaira M, Yonemori K, Shimizu C, Ando M, Masutomi K, Yoshida T, Fujiwara Y, Tamura K.

Cancer Sci. 2012 Sep;103(9):1665-71. doi: 10.1111/j.1349-7006.2012.02359.x. Epub 2012 Aug 1.

33.

Simultaneous determination of dextromethorphan, dextrorphan and doxylamine in human plasma by HPLC coupled to electrospray ionization tandem mass spectrometry: application to a pharmacokinetic study.

Donato JL, Koizumi F, Pereira AS, Mendes GD, De Nucci G.

J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Jun 15;899:46-56. doi: 10.1016/j.jchromb.2012.05.001. Epub 2012 May 6.

PMID:
22651995
34.

FGFR2 gene amplification and clinicopathological features in gastric cancer.

Matsumoto K, Arao T, Hamaguchi T, Shimada Y, Kato K, Oda I, Taniguchi H, Koizumi F, Yanagihara K, Sasaki H, Nishio K, Yamada Y.

Br J Cancer. 2012 Feb 14;106(4):727-32. doi: 10.1038/bjc.2011.603. Epub 2012 Jan 12.

35.

N-cadherin expression is a potential survival mechanism of gefitinib-resistant lung cancer cells.

Yamauchi M, Yoshino I, Yamaguchi R, Shimamura T, Nagasaki M, Imoto S, Niida A, Koizumi F, Kohno T, Yokota J, Miyano S, Gotoh N.

Am J Cancer Res. 2011;1(7):823-33. Epub 2011 Aug 8.

36.

Serum heparan sulfate concentration is correlated with the failure of epidermal growth factor receptor tyrosine kinase inhibitor treatment in patients with lung adenocarcinoma.

Nishio M, Yamanaka T, Matsumoto K, Kimura H, Sakai K, Sakai A, Sone T, Horiike A, Koizumi F, Kasahara K, Ohira T, Ikeda N, Saijo N, Arao T, Nishio K.

J Thorac Oncol. 2011 Nov;6(11):1889-94. doi: 10.1097/JTO.0b013e3182286d41.

37.

Acquired drug resistance to vascular endothelial growth factor receptor 2 tyrosine kinase inhibitor in human vascular endothelial cells.

Arao T, Matsumoto K, Furuta K, Kudo K, Kaneda H, Nagai T, Sakai K, Fujita Y, Tamura D, Aomatsu K, Koizumi F, Nishio K.

Anticancer Res. 2011 Sep;31(9):2787-96.

PMID:
21868521
38.

Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3.

Kodera Y, Katanasaka Y, Kitamura Y, Tsuda H, Nishio K, Tamura T, Koizumi F.

Breast Cancer Res. 2011 Jun 21;13(3):R66. doi: 10.1186/bcr2903.

39.

Phase I dose-escalation study and biomarker analysis of E7080 in patients with advanced solid tumors.

Yamada K, Yamamoto N, Yamada Y, Nokihara H, Fujiwara Y, Hirata T, Koizumi F, Nishio K, Koyama N, Tamura T.

Clin Cancer Res. 2011 Apr 15;17(8):2528-37. doi: 10.1158/1078-0432.CCR-10-2638. Epub 2011 Mar 3.

40.

FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer.

Tamura K, Shimizu C, Hojo T, Akashi-Tanaka S, Kinoshita T, Yonemori K, Kouno T, Katsumata N, Ando M, Aogi K, Koizumi F, Nishio K, Fujiwara Y.

Ann Oncol. 2011 Jun;22(6):1302-7. doi: 10.1093/annonc/mdq585. Epub 2010 Nov 25.

PMID:
21109570
41.

Efficacy of RAD001 (everolimus) against advanced gastric cancer with peritoneal dissemination.

Taguchi F, Kodera Y, Katanasaka Y, Yanagihara K, Tamura T, Koizumi F.

Invest New Drugs. 2011 Dec;29(6):1198-205. doi: 10.1007/s10637-010-9464-9. Epub 2010 Jun 8.

PMID:
20532589
42.

Cancer antineovascular therapy with liposome drug delivery systems targeted to BiP/GRP78.

Katanasaka Y, Ishii T, Asai T, Naitou H, Maeda N, Koizumi F, Miyagawa S, Ohashi N, Oku N.

Int J Cancer. 2010 Dec 1;127(11):2685-98. doi: 10.1002/ijc.25276.

43.

MicroRNA-500 as a potential diagnostic marker for hepatocellular carcinoma.

Yamamoto Y, Kosaka N, Tanaka M, Koizumi F, Kanai Y, Mizutani T, Murakami Y, Kuroda M, Miyajima A, Kato T, Ochiya T.

Biomarkers. 2009 Nov;14(7):529-38. doi: 10.3109/13547500903150771.

PMID:
19863192
44.

Synergistic interactions between the synthetic retinoid tamibarotene and glucocorticoids in human myeloma cells.

Fukui T, Kodera Y, Nishio K, Masuda N, Tamura T, Koizumi F.

Cancer Sci. 2009 Jun;100(6):1137-43.

45.

Circulating endothelial cells in non-small cell lung cancer patients treated with carboplatin and paclitaxel.

Kawaishi M, Fujiwara Y, Fukui T, Kato T, Yamada K, Ohe Y, Kunitoh H, Sekine I, Yamamoto N, Nokihara H, Watabe T, Shimoda Y, Arao T, Nishio K, Tamura T, Koizumi F.

J Thorac Oncol. 2009 Feb;4(2):208-13. doi: 10.1097/JTO.0b013e318193030d.

46.

Identification of predictive biomarkers for response to trastuzumab using plasma FUCA activity and N-glycan identified by MALDI-TOF-MS.

Matsumoto K, Shimizu C, Arao T, Andoh M, Katsumata N, Kohno T, Yonemori K, Koizumi F, Yokote H, Aogi K, Tamura K, Nishio K, Fujiwara Y.

J Proteome Res. 2009 Feb;8(2):457-62. doi: 10.1021/pr800655p.

PMID:
19140672
47.

Antitumor activity of cetuximab against malignant glioma cells overexpressing EGFR deletion mutant variant III.

Fukai J, Nishio K, Itakura T, Koizumi F.

Cancer Sci. 2008 Oct;99(10):2062-9. doi: 10.1111/j.1349-7006.2008.00945.x.

48.

Identification of prognostic biomarkers in gastric cancer using endoscopic biopsy samples.

Yamada Y, Arao T, Gotoda T, Taniguchi H, Oda I, Shirao K, Shimada Y, Hamaguchi T, Kato K, Hamano T, Koizumi F, Tamura T, Saito D, Shimoda T, Saka M, Fukagawa T, Katai H, Sano T, Sasako M, Nishio K.

Cancer Sci. 2008 Nov;99(11):2193-9. doi: 10.1111/j.1349-7006.2008.00935.x. Epub 2008 Jan 11.

49.

[Biomarker strategy for cancer treatment and cancer drug development].

Koizumi F.

Nihon Yakurigaku Zasshi. 2008 Aug;132(2):105-10. Review. Japanese. No abstract available.

PMID:
18689960
50.

Antiangiogenic cancer therapy using tumor vasculature-targeted liposomes encapsulating 3-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one, SU5416.

Katanasaka Y, Ida T, Asai T, Shimizu K, Koizumi F, Maeda N, Baba K, Oku N.

Cancer Lett. 2008 Nov 8;270(2):260-8. doi: 10.1016/j.canlet.2008.05.009. Epub 2008 Jun 13.

PMID:
18555591

Supplemental Content

Loading ...
Support Center